Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

57.69 +2.07 (+3.71%)
Streaming Delayed Price Updated: 1:23 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days. 
Via Benzinga
US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’
Via Stocktwits
Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over?
Novo Nordisk has been in a downtrend for more than a year. But a reversal may be underway, and a rally may follow. 
Via Benzinga
Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study
Via Stocktwits
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment
Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients. 
Via Benzinga
Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report
Via Stocktwits
Why Is Novo Nordisk’s Stock Rising Premarket Today?
Via Stocktwits
Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’
Via Stocktwits
3 Undervalued Healthcare Stocks to Buy Now While They're Cheap
In an otherwise hot stock market, healthcare stocks are underperforming. 
Via The Motley Fool
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders
The weight loss drug market may reach $95 billion within five years. 
Via The Motley Fool
What's Going On With Novo Nordisk Shares Monday?
Novo Nordisk shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke. 
Via Benzinga
Novo Nordisk's Rybelsus Now First Oral GLP-1 RA In Europe With Proven Heart Health Impact
EMA approved Rybelsus' label update after the SOUL trial showed it cuts heart attack, stroke, and death by 14% in high-risk type 2 diabetes patients. 
Via Benzinga
Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition
Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance.... 
Via MarketMinute
Topics Economy Intellectual Property
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
Why Novo Nordisk Stock Popped Today
A price cut could help get Novo Nordisk stock back in the race against Eli Lilly. 
Via The Motley Fool
Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks
FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA... 
Via Benzinga
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
How Do Investors Really Feel About Novo Nordisk?
 
Via Benzinga
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback
One of them is already a leader in the market for weight management drugs, and the other could join this field. 
Via The Motley Fool
Topics ETFs
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades
A decade from now, you could regret ignoring these no-brainer stock picks. 
Via The Motley Fool
Topics Intellectual Property
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
Novo Nordisk Tightens Its Belt, Cutting 9,000 Jobs And Its Profit Outlook
Novo Nordisk announced a "sweeping transformation" Wednesday as the drugmaker contends with challenges in obesity. 
Via Investor's Business Daily
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices. 
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Prime Value Candidate with Strong Fundamentals
Discover Novo Nordisk (NVO), a strong value investing candidate. It offers solid valuation, top-tier profitability, and robust growth in the pharmaceutical sector. 
Via Chartmill
Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'
Novo Nordisk (NYSE: NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant... 
Via Benzinga
Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'
Novartis agreed to buy a cardiovascular-focused biotech company 
Via Investor's Business Daily
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company. 
Via Investor's Business Daily
1 Reason Every Investor Should Know About Novo Nordisk (NVO)
The company could be on the verge of turning the tide in the battle over weight loss drugs. 
Via The Motley Fool
Ozempic Is The New Botox And Big Pharma Is Printing Billions
Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion. 
Via Benzinga
FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List
FDA introduces a green list to block unsafe GLP-1 drug imports, while WHO updates its essential medicines list to include diabetes and cancer treatments. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.